To monitor the changes in the protein levels of FGF9, ki-67, MMP-2, and MMP-9, we performed immunoblotting following the methods described before [55 (link)] with antibodies against CD206, CD16, FGF9, ki-67, MMP-2, and MMP-9 (ab64693, ab46679, ab71395, ab15580, and ab38898, Abcam, Cambridge, UK) followed by another incubation with the appropriate HRP-conjugated secondary antibodies. GAPDH (ab16891, Abcam) was used as an endogenous control. Signals were visualized using enhanced chemiluminescent (ECL) substrates (WBKlS0100, Millipore, MA, USA) and were normalized to the GAPDH signal.
Free full text: Click here